Research ArticleArticle
Clinical Remission in Patients with Active Psoriatic Arthritis Treated with Adalimumab and Correlations in Joint and Skin Manifestations
Filip Van den Bosch, Arthur Kavanaugh, Martina Kron, Hartmut Kupper and Philip J. Mease
The Journal of Rheumatology April 2015, jrheum.140312; DOI: https://doi.org/10.3899/jrheum.140312
Filip Van den Bosch
From the Ghent University Hospital, Ghent, Belgium; University of California at San Diego, La Jolla, California; University of Washington, Swedish Medical Center, Seattle, Washington, USA; AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany. AbbVie Inc. sponsored the study (), contributed to its design, participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final manuscript. F. Van den Bosch has received consulting fees and speaker’s fees from AbbVie Inc. A. Kavanaugh has received grant/research and/or provided expert advice to AbbVie Inc. P.J. Mease has received consulting fees, research grants, and/or speaker honoraria from AbbVie Inc. M. Kron and H. Kupper are full-time employees of AbbVie Deutschland GmbH & Co. KG and may hold stock or stock options. F. Van den Bosch, MD, PhD, Ghent University Hospital; A. Kavanaugh, MD, University of California at San Diego; M. Kron, PhD; H. Kupper, MD, AbbVie Deutschland GmbH & Co KG; P.J. Mease, MD, University of Washington, Swedish Medical Center. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, Washington 98122, USA. E-mail: pmease@philipmease.com. Accepted for publication January 21, 2015.
Arthur Kavanaugh
From the Ghent University Hospital, Ghent, Belgium; University of California at San Diego, La Jolla, California; University of Washington, Swedish Medical Center, Seattle, Washington, USA; AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany. AbbVie Inc. sponsored the study (), contributed to its design, participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final manuscript. F. Van den Bosch has received consulting fees and speaker’s fees from AbbVie Inc. A. Kavanaugh has received grant/research and/or provided expert advice to AbbVie Inc. P.J. Mease has received consulting fees, research grants, and/or speaker honoraria from AbbVie Inc. M. Kron and H. Kupper are full-time employees of AbbVie Deutschland GmbH & Co. KG and may hold stock or stock options. F. Van den Bosch, MD, PhD, Ghent University Hospital; A. Kavanaugh, MD, University of California at San Diego; M. Kron, PhD; H. Kupper, MD, AbbVie Deutschland GmbH & Co KG; P.J. Mease, MD, University of Washington, Swedish Medical Center. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, Washington 98122, USA. E-mail: pmease@philipmease.com. Accepted for publication January 21, 2015.
Martina Kron
From the Ghent University Hospital, Ghent, Belgium; University of California at San Diego, La Jolla, California; University of Washington, Swedish Medical Center, Seattle, Washington, USA; AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany. AbbVie Inc. sponsored the study (), contributed to its design, participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final manuscript. F. Van den Bosch has received consulting fees and speaker’s fees from AbbVie Inc. A. Kavanaugh has received grant/research and/or provided expert advice to AbbVie Inc. P.J. Mease has received consulting fees, research grants, and/or speaker honoraria from AbbVie Inc. M. Kron and H. Kupper are full-time employees of AbbVie Deutschland GmbH & Co. KG and may hold stock or stock options. F. Van den Bosch, MD, PhD, Ghent University Hospital; A. Kavanaugh, MD, University of California at San Diego; M. Kron, PhD; H. Kupper, MD, AbbVie Deutschland GmbH & Co KG; P.J. Mease, MD, University of Washington, Swedish Medical Center. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, Washington 98122, USA. E-mail: pmease@philipmease.com. Accepted for publication January 21, 2015.
Hartmut Kupper
From the Ghent University Hospital, Ghent, Belgium; University of California at San Diego, La Jolla, California; University of Washington, Swedish Medical Center, Seattle, Washington, USA; AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany. AbbVie Inc. sponsored the study (), contributed to its design, participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final manuscript. F. Van den Bosch has received consulting fees and speaker’s fees from AbbVie Inc. A. Kavanaugh has received grant/research and/or provided expert advice to AbbVie Inc. P.J. Mease has received consulting fees, research grants, and/or speaker honoraria from AbbVie Inc. M. Kron and H. Kupper are full-time employees of AbbVie Deutschland GmbH & Co. KG and may hold stock or stock options. F. Van den Bosch, MD, PhD, Ghent University Hospital; A. Kavanaugh, MD, University of California at San Diego; M. Kron, PhD; H. Kupper, MD, AbbVie Deutschland GmbH & Co KG; P.J. Mease, MD, University of Washington, Swedish Medical Center. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, Washington 98122, USA. E-mail: pmease@philipmease.com. Accepted for publication January 21, 2015.
Philip J. Mease
From the Ghent University Hospital, Ghent, Belgium; University of California at San Diego, La Jolla, California; University of Washington, Swedish Medical Center, Seattle, Washington, USA; AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany. AbbVie Inc. sponsored the study (), contributed to its design, participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final manuscript. F. Van den Bosch has received consulting fees and speaker’s fees from AbbVie Inc. A. Kavanaugh has received grant/research and/or provided expert advice to AbbVie Inc. P.J. Mease has received consulting fees, research grants, and/or speaker honoraria from AbbVie Inc. M. Kron and H. Kupper are full-time employees of AbbVie Deutschland GmbH & Co. KG and may hold stock or stock options. F. Van den Bosch, MD, PhD, Ghent University Hospital; A. Kavanaugh, MD, University of California at San Diego; M. Kron, PhD; H. Kupper, MD, AbbVie Deutschland GmbH & Co KG; P.J. Mease, MD, University of Washington, Swedish Medical Center. Address correspondence to Dr. P.J. Mease, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, Washington 98122, USA. E-mail: pmease@philipmease.com. Accepted for publication January 21, 2015.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Clinical Remission in Patients with Active Psoriatic Arthritis Treated with Adalimumab and Correlations in Joint and Skin Manifestations
Filip Van den Bosch, Arthur Kavanaugh, Martina Kron, Hartmut Kupper, Philip J. Mease
The Journal of Rheumatology Apr 2015, jrheum.140312; DOI: 10.3899/jrheum.140312
Clinical Remission in Patients with Active Psoriatic Arthritis Treated with Adalimumab and Correlations in Joint and Skin Manifestations
Filip Van den Bosch, Arthur Kavanaugh, Martina Kron, Hartmut Kupper, Philip J. Mease
The Journal of Rheumatology Apr 2015, jrheum.140312; DOI: 10.3899/jrheum.140312